On this page
How do you prepare clean and annotated draft labeling?
Identify the applicable labeling requirements and named baseline, then draft only supported proposed text. For an NDA, 314.50(c)(2)(i) addresses annotations to the information supporting labeling statements; an ANDA needs its own RLD comparison and explained differences. Keep evidence references, change explanations and agency-comment responses traceable, and verify that the clean and annotated copies contain the same substantive proposal.
Before you begin
Preparation of proposed labeling text. Resolve the applicable NDA, ANDA or BLA labeling requirements, label format and submission route before using the outline. This guide does not supply product claims or dosing recommendations.
What you will prepare: A clean proposed label and an annotated companion that ties each material claim or change to its source and decision.
Sections covered in this guide (3)
Freeze the starting text and the question
For an NDA, 314.50(c)(2)(i) addresses proposed labeling text with annotations to the supporting NDA information; 314.50(e)(2) separately addresses labeling copies. An ANDA instead needs the reference-label comparison and explained differences described in 314.94(a)(8). Identify the applicable route before drafting. Record the baseline version and the specific decision being requested: initial content, response to comments, new evidence or a defined change. Obtain the scientific and regulatory owners’ rationale; a writer should not manufacture an indication or broaden a studied population.
Build a claim-to-evidence worksheet
| Proposed passage | Evidence needed | Editorial check |
|---|---|---|
| Population or indication | Relevant study population and proposed claim rationale | Does the wording extend beyond the evidence? |
| Administration instruction | Supported regimen and preparation/use records | Do units, route and sequence agree across documents? |
| Risk statement | Assessed safety evidence and decision record | Are context and uncertainty preserved? |
| Storage or handling | Applicable controlled quality information | Is the presentation and in-use condition the same? |
For each item, record a pinpoint source and the responsible reviewer. Separate an unresolved proposal from language accepted in a prior exchange. This worksheet is an editorial aid, not a set of claims to paste into a label.
Keep clean and annotated copies synchronized
Maintain the same substantive text in both copies. Put evidence locations and explanations in the annotations; make additions, deletions and responses to agency comments traceable against the named baseline. Give each comment a disposition and destination. Review cross-references after pagination changes. If a supporting table uses a different analysis cutoff, do not cite it as if it substantiates the proposed number; obtain the correct source or revise the proposal.
Fictional example: a broader population claim
A proposed sentence says “all adults,” while the cited report excludes a relevant subgroup. The preparation output is an issue record identifying the mismatch, the source population and the owner who must resolve the claim. It is not a rewritten claim pretending the missing evidence exists. When new supporting data arrive, update both label copies and the annotation, then recheck dependent patient information and packaging instructions.
Distinguish evidence annotations from change annotations
A redline shows what changed. It does not necessarily show why the proposed statement is supported. Build the evidence record and the baseline comparison as related, separately understandable views of the same proposed text.
| Annotation element | What a reviewer needs | Incomplete substitute |
|---|---|---|
| Proposed passage | Exact wording and stable location in the current draft | A general section name without the actual statement |
| Evidence | Source document/version, section or table, and relevant finding | “See clinical data” without a usable locator |
| Applicability | Population, formulation, regimen, cutoff and analysis relevant to the claim | A result from a different product version or population |
| Change rationale | Why this wording differs from the named baseline | Tracked changes with no reason |
| Agency comment | Exact comment identifier, response and resulting text | A closed comment whose requested change was never implemented |
| Remaining question | Missing evidence or interpretation, accountable owner and disposition | Wording softened just enough to hide the unresolved issue |
For an NDA, 314.50(c)(2)(i) also addresses reasons for omitting a section or subsection of the prescription-labeling format. Do not remove a section solely because the source template did not contain it. Establish the applicable format and rationale with the responsible reviewer. Section 314.50(e)(2) concerns labeling copies; it is not the locator for the annotation-support requirement.
Fictional annotation exercise: a proposed percentage is supported by a table from an earlier data cutoff, while the cited report was subsequently revised. Open the actual cited version, identify the analysis population and denominator, and reconcile the proposed number. If the newer report changes the interpretation, route that issue to the scientific and regulatory owners. Merely updating the link to the newest PDF does not establish that the old claim is still supported.
Give a change one traceable identity across the draft, response document and history. If FDA's comment has several parts, record each disposition. “Addressed” should mean that the intended revised text and supporting response can be found, not just that someone replied in a working document.
Before release, compare substantive text independently of annotations and styling. Check additions and deletions, numbers, units, punctuation that changes meaning, tables, headings and cross-references. Recheck locators after a report or page layout changes. Preserve missing support as an open issue rather than deleting its annotation to make the copy look clean.
Use the labeling history for the decision trail and the final-package guide for rendition reconciliation. For an ANDA, use the reference-labeling comparison instead of treating an NDA evidence rationale as permission for a generic-label difference.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is a tracked-changes label the same as an evidence-annotated label?
No. Tracked changes identify differences from a baseline; evidence annotations identify the information supporting the proposed statements. A useful review package makes both understandable. Record the named baseline, exact supporting source and change rationale rather than assuming a redline alone explains the scientific basis.
Which NDA provision addresses annotations supporting labeling statements?
Section 314.50(c)(2)(i) addresses proposed labeling text annotated to supporting information in the NDA summary and technical sections. Section 314.50(e)(2) separately addresses labeling copies. Use the correct locator and establish the submission context rather than attributing both requirements to the copies provision.
Can the clean label contain wording that differs from the annotated copy?
The two copies should represent the same substantive proposal. Resolve differences in wording, numbers, tables or cross-references before handoff, and identify the controlled version. A reviewer cannot reliably evaluate a claim when the evidence annotations accompany a different sentence from the one actually proposed.
What if the cited study does not support the proposed population or number?
Record the mismatch and obtain the correct evidence or a reviewed change to the proposal. Check the source version, population, analysis and cutoff. Do not broaden a claim or substitute a nearby result merely to close an annotation, and do not hide the unresolved issue by removing the citation.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR 314.50: NDA content and labeling ↗Paragraphs (c)(2)(i), (e)(2) and (l). Current eCFR reopened October 6, 2026, displaying currency through October 2, 2026. Annotated proposed text and labeling copies are separate provisions.
Regulation
21 CFR 314.94: ANDA labeling ↗Paragraph (a)(8), including reference labeling, comparison and explained differences. Current eCFR reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.14.1. A heading identifies placement, not mandatory applicability.